Emma Verner

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

Constantine S. Tam, Jennifer R. Brown, Brad S. Kahl et al. · The Lancet Oncology · 2022 · 278 citations · Full text

Medicine, Oncology, Pharmacology +8

Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion

Constantine S. Tam, Tadeusz Robak, Paolo Ghia et al. · Haematologica · 2020 · 103 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA

Mazyar Shadman, Talha Munir, Tadeusz Robak et al. · Journal of Clinical Oncology · 2024 · 57 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Zanubrutinib for treatment‐naïve and relapsed/refractory chronic lymphocytic leukaemia: long‐term follow‐up of the phase I/II AU‐003 study

Gavin Cull, Jan A. Burger, Stephen Opat et al. · British Journal of Haematology · 2021 · 40 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial

Jennifer R. Brown, Tadeusz Robak, Paolo Ghia et al. · Blood · 2020 · 36 citations

Medicine, Oncology, Pharmacology +9